Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25011614 | 0.89 | CRBN (0.57) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL26058032 | 0.88 | CRBN (0.66) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL31444087 | 0.88 | CRBN (0.66) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL24294412 | 0.87 | CRBN (0.58) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL30304165 | 0.86 | CRBN (0.67) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL30270628 | 0.86 | CRBN (0.55) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL25012124 | 0.86 | CRBN (0.55) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL30270867 | 0.86 | CRBN (0.57) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL25011325 | 0.86 | CRBN (0.57) | CRBNDDB1IKZF1IKZF3BRD4 | |
| SCHEMBL26102151 | 0.86 | CRBN (0.67) | CRBNDDB1IKZF1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | VIVIDION THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | VIVIDION THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022266258-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 | ARVINAS OPERATIONS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | CRBN, CLNS1A, CDR2 | CRBN 1/4885DDB1 1070/4885IKZF1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.